ARA-290 Information & Coordination for Licensed U.S. Clinics

ARA-290, also known as cibinetide, is identified as an ingredient substance in the U.S. Food and Drug Administration’s (FDA) Global Substance Registration System. Its record carries the Unique Ingredient Identifier (UNII) 9W5677JKDA.

The existence of a UNII does not establish regulatory review or FDA approval of a finished drug product. The FDA’s list of bulk drug substances nominated for use in compounding under Section 503A, updated May 14, 2026, includes Cibinetide (ARA-290) in Category 3, for substances nominated without adequate supporting information.

Phoenix Meds Inc. provides administrative coordination and documentation support for licensed U.S. healthcare organizations. We are not a pharmacy, medical practice, drug manufacturer, prescriber, or dispensing entity.

What Clinics Should Know About ARA-290

ARA-290 and cibinetide are names associated with the substance identified in the FDA database. That identification should not be confused with approval of a finished medication or confirmation that a particular preparation meets applicable regulatory requirements.

A substance record identifies information associated with an ingredient. It does not independently establish the identity, composition, quality, safety, effectiveness, or legal status of a particular preparation.

This page does not present ARA-290 as an FDA-approved treatment or recommend its use for a medical condition. It provides regulatory information and explains the limited administrative role of Phoenix Meds.

Visit our medication information page for an overview of specialty medication topics & related regulatory considerations.

ARA-290 (Cibinetide) 10mg - 5ml peptide

Current FDA and Compounding Status

In the FDA’s May 14, 2026 list of bulk drug substances nominated for use in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act, Cibinetide (ARA-290) appears in Category 3, titled “Bulk Drug Substances Nominated Without Adequate Support.”

The FDA explains that Category 3 substances were nominated without sufficient supporting information for the agency to evaluate them. These substances are not eligible for the interim enforcement policy that applies to certain Category 1 substances. The FDA states that it may consider enforcement action under its general enforcement policies when a drug product is compounded using a Category 3 substance.

This classification is not FDA approval and does not authorize a particular preparation to be compounded. The Category 3 nomination list is also distinct from the final Section 503A Bulks List.

Sections 503A and 503B establish different conditions for human drug compounding. A pharmacy’s license or an outsourcing facility’s FDA registration does not, by itself, establish that every substance or preparation may be used in compounding. The applicable requirements must be assessed in the relevant circumstances by the parties legally responsible for those decisions.

Why Product Identity Matters

A database entry, label, certificate, or other document should be considered in context. No single identifier or document automatically establishes every relevant fact about a particular preparation.

Depending on the records available, an administrative review may identify questions about:

  • Whether substance names and identifiers are consistent across the available records.
  • Whether the documents identify the relevant organizations and responsible professionals.
  • Whether records are complete and whether any information remains unresolved.
  • Whether a question requires review by an appropriately qualified pharmacy, regulatory, clinical, or legal professional.

Organizing documents does not independently verify a preparation’s identity, concentration, purity, potency, sterility, stability, safety, effectiveness, or eligibility for compounding. Those matters must be addressed by the appropriately qualified and legally responsible parties.

How Phoenix Meds Supports Licensed Clinics

Phoenix Meds’ role is administrative. Depending on the engagement, our services may include:

  • Credential documentation: Organizing available clinic and provider credential records.
  • Regulatory information: Reviewing publicly available licensing and regulatory information for administrative reference.
  • Document organization: Arranging available records so the appropriate professionals can review them.
  • Administrative communication: Coordinating communications between relevant professional organizations.
  • Documentation follow-up: Identifying missing information or unresolved questions that may require further professional review.

Our work is intended to support administrative recordkeeping and communication. We do not make clinical, prescribing, dispensing, product-specific compounding, or legal eligibility decisions.

Phoenix Meds does not manufacture, test, compound, dispense, ship, or take custody of ARA-290. We do not independently certify the identity, purity, potency, sterility, stability, safety, effectiveness, or quality of any preparation.

ARA-290 Administrative Coordination for Licensed Clinics

Licensed healthcare organizations may have administrative requirements involving professional credentials, documentation, publicly available regulatory records, and communication between relevant parties. Phoenix Meds provides administrative support within the scope of its services. 

Clinic Verification

Licensed healthcare organizations may submit relevant professional and facility credentials for administrative verification.

Documentation Review

Phoenix may help organize available documentation and publicly available regulatory information so the clinic can identify matters that need further review.

Licensed Parties

Prescribing, compounding, dispensing, distribution, storage, shipping, and other regulated medication activities remain with the parties legally authorized and responsible for performing them.

Frequently Asked Questions

Yes. The FDA’s Global Substance Registration System identifies cibinetide as an ingredient substance and lists ARA-290 among its synonyms. The record does not establish approval of a finished drug product.

No. The FDA expressly states that a UNII does not imply regulatory review or approval. Product approval must be established separately through the relevant official records.

The FDA’s list updated May 14, 2026, places Cibinetide (ARA-290) in Category 3 for substances nominated without adequate supporting information. These substances are not eligible for the interim enforcement policy applicable to certain Category 1 substances, and the FDA may consider enforcement under its general policies.

No. The listing does not grant blanket authorization to compound a preparation. The applicable statutory requirements and circumstances must be evaluated by the legally responsible parties.

No. Phoenix Meds provides administrative coordination and documentation support. Clinical, prescribing, dispensing, compounding, and product-specific legal determinations remain with the appropriately qualified and legally responsible parties.

No. Phoenix Meds does not independently test or certify product identity, purity, potency, sterility, stability, safety, effectiveness, or quality.

Depending on the engagement, Phoenix Meds may help organize available documentation, review publicly available licensing information, coordinate administrative communications, and identify documentation questions that require further professional review.

Important Notice

Phoenix Meds Inc. provides administrative coordination and documentation support for licensed U.S. healthcare organizations. We are not a pharmacy, medical practice, drug manufacturer, outsourcing facility, prescriber, or dispensing entity.

This page is for professional informational purposes. It is not medical advice, a treatment recommendation, or a legal opinion. A substance database entry or administrative document review does not establish FDA approval, product quality, clinical suitability, product availability, or eligibility for compounding.

Regulatory information may change. Product-specific questions should be assessed using current official records and the facts relevant to the circumstances by appropriately qualified professionals.

Scroll to Top

Thank You!

Your order has been placed successfully.

Order Number #14327
Date May 19, 2025
Payment Method Credit Card (Stripe)
Please look out for an email from FedEx when your order ships.
Continue Shopping  ›